Company profile
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. The company offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment clinical blood test targeting CHD events, including heart attacks; PrecisionCHD, an integrated epigenetic-genetic clinical blood test for the detection of coronary heart disease; and Actionable Clinical Intelligence, a platform that offers new epigenetic and genetic insights
- CEO
- Dr. Meeshanthini V. Dogan Ph.D.
- Headquarters
- Chicago, IL, United States
- Employees
- 15
- IPO date
- Jan 14, 2022
- Sector
- Healthcare
- Industry
- Biotechnology